Unlock instant, AI-driven research and patent intelligence for your innovation.

Oligo-nucleic acid for suppressing tumor growth and application thereof

An oligomeric nucleic acid and tumor technology, applied in the field of oligomeric nucleic acid, to achieve long-effect half-life, enhance anti-tumor effect, and prevent tumor growth

Active Publication Date: 2013-11-20
SHENZHEN GRADUATE SCHOOL TSINGHUA UNIV +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the expression of miR-34 is inhibited in a variety of tumors, so the development of miR-34 mimics for tumor therapy may achieve good results

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oligo-nucleic acid for suppressing tumor growth and application thereof
  • Oligo-nucleic acid for suppressing tumor growth and application thereof
  • Oligo-nucleic acid for suppressing tumor growth and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Embodiment 1, the preparation of oligomeric nucleic acid

[0037] The sense strand of the oligomeric nucleic acid sequence described in the present invention is: 5'-UGGCAGUGUCUUAGCUGGUUGU-3' (SEQ ID No.1); the antisense strand is 3'-UCCCGUCAUAUGAACGACUAAC-5' (SEQ ID No.2) or 3'-UUACCGUCACAGAAAUCGACCAA -5' (SEQ ID No. 3). A random sequence was selected as a negative control (NC). The sense strand sequence of NC is: 5'-UUCUCCGAACGUGUCACGUTT-3' (SEQ ID No.4), and the antisense strand sequence is: 3'-TTAAGAGGCUUGCACAGUGCA-5' (SEQ ID No. .5). A, G, C, and U in the oligonucleotide and NC sequences represent adenine ribonucleotides, guanine ribonucleotides, cytosine ribonucleotides and uracil ribonucleotides, and T represents thymine deoxynucleotides.

[0038] The oligonucleotide and NC were commissioned by Shanghai GenePharma Pharmaceutical Technology Co., Ltd. to synthesize and perform any of the following chemical modifications: 2'methoxy (2'-OMe), 2'fluoro (2'-F ), thi...

Embodiment 2

[0050] Effect of embodiment 2, 2'-OMe-oligonucleotide on tumor cell proliferation

[0051] The experimental procedure is as follows: 2'-OMe-miR-34a, 2'-OMe-miR-34a* (abbreviated as miR-34a and miR-34a* in the figure) obtained in Example 1 and 2'-OMe-NC (Fig. (hereinafter referred to as NC) powder was dissolved in RNase-free sterile water to prepare three kinds of oligonucleotide solutions with a final concentration of 20 pmol / L. Collect logarithmic phase HCT116 intestinal cancer cells (purchased from Peking Union Medical College Cell Bank), adjust the concentration of cell suspension, and divide them into 24-well plates with 10,000 cells per well, add IMDM culture medium containing 2.5% fetal bovine serum (purchased from GIBCO) at 37°C with 5% CO 2 Incubate in an incubator for 16-24 hours. For transfection, 2 μl of oligonucleotide solution and 1 μl of lipofectamine 2000 (Invitrogen) were diluted in 50 μl of serum-free medium (Opti-MEM) (purchased from GIBCO), and incubated a...

Embodiment 3

[0054] Example 3, Half-life test detection of 2'-OMe-oligonucleotide inhibiting tumor cell expression CCND1

[0055] Using Invitrogen's lipofectamine TM 2000 liposomes were used for transfection, and all operations were performed according to the operating procedures provided by Invitrogen. Inoculate HCT 116 cells into a 6-well plate (200,000 cells / well), culture with IMDM medium containing 2.5% fetal bovine serum (purchased from GIBCO) for 16-24 hours, then replace the cell culture medium with antibiotic-free IMDM medium. Dissolve miR-34a*, 2′-OMe-miR-34a*, NC and 2′-OMe-NC powders in RNase-free sterile water to prepare 4 kinds of oligonucleotides with a final concentration of 20pmol / L solution. For transfection, take 10 μl of the above oligonucleotide solution and 5 μl of lipofectamine 2000 and dilute them in 250 μl of serum-free culture medium (Opti-MEM), and incubate at room temperature for 5 minutes, then the above oligonucleotide solution Mix with lipofectamine 2000 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses oligo-nucleic acid for suppressing tumor growth and application thereof. The oligo-nucleic acid is double-chain RNA (Ribonucleic Acid), wherein the nucleotide sequence of a first chain of the double-chain RNA is shown as a sequence 1 in a sequence table; and the nucleotide sequence of a second chain has over 68.2 percent of homology with a reverse complementary chain of the first chain and can be specifically shown as a sequence 2 or a sequence 3. The oligo-nucleic acid provided by the invention can be taken as a novel small ribonucleic acid anti-tumor drug. When the oligo-nucleic acid is used in combination with oligonucleotide (2'-OMe-siVEGF) of a silent vascular endothelial growth factor (VEGF), the anti-tumor effect of the oligo-nucleic acid can be enhanced.

Description

technical field [0001] The present invention relates to oligomeric nucleic acid for inhibiting tumor growth and its application. Background technique [0002] Micronucleic acid (miRNA) is a kind of non-coding small nucleic acid that exists naturally in the body and is widely distributed. It mainly participates in important physiological and pathological processes of the body through post-transcriptional regulation of genes. Dysregulation of micronucleic acid is closely related to the occurrence, development and prognosis of many diseases, including tumors. In recent years, studies have found that there are significant differences in the expression profiles of miRNAs between tumor cells and normal tissue cells. miRNA can not only promote the occurrence and development of tumors as proto-oncogenes, but also inhibit the occurrence and development of tumors as tumor suppressor genes. Therefore, the study of miRNAs can not only deepen the understanding of tumor pathophysiologica...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/113C12N15/11A61K48/00A61P35/00
Inventor 张雅鸥李建娜谢伟东何杰张佩琢
Owner SHENZHEN GRADUATE SCHOOL TSINGHUA UNIV